CURIS INC
Biotechnology company developing and commercializing therapeutics for cancer treatment.
CRIS | US
Overview
Corporate Details
- ISIN(s):
- US2312693094
- LEI:
- Country:
- United States of America
- Address:
- 128 SPRING STREET, 2421 LEXINGTON
- Website:
- https://www.curis.com/
- Sector:
- Manufacturing
Description
Curis, Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. The company's clinical pipeline is led by emavusertib (CA-4948), a small molecule inhibitor of the IRAK4 kinase, being investigated for hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and non-Hodgkin lymphoma (NHL). Additional clinical-stage programs include fimepinostat, a dual inhibitor of HDAC and PI3K for MYC-altered cancers, and CA-170, an oral antagonist targeting the VISTA and PDL1 immune checkpoints. The company's portfolio also includes Erivedge, a Hedgehog pathway inhibitor approved for basal cell carcinoma and licensed to Genentech.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CURIS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CURIS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CURIS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
